CRVS
Price
$8.91
Change
-$0.18 (-1.98%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
665.42M
105 days until earnings call
Intraday BUY SELL Signals
HIND
Price
$4.59
Change
-$0.38 (-7.65%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
25.84M
Intraday BUY SELL Signals
Interact to see
Advertisement

CRVS vs HIND

Header iconCRVS vs HIND Comparison
Open Charts CRVS vs HINDBanner chart's image
Corvus Pharmaceuticals
Price$8.91
Change-$0.18 (-1.98%)
Volume$14.95K
Capitalization665.42M
Vyome Holdings
Price$4.59
Change-$0.38 (-7.65%)
Volume$1.31K
Capitalization25.84M
CRVS vs HIND Comparison Chart in %
CRVS
Daily Signal:
Gain/Loss:
HIND
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CRVS vs. HIND commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRVS is a Hold and HIND is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (CRVS: $8.91 vs. HIND: $4.59)
Brand notoriety: CRVS and HIND are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRVS: 76% vs. HIND: 11%
Market capitalization -- CRVS: $665.42M vs. HIND: $25.84M
CRVS [@Biotechnology] is valued at $665.42M. HIND’s [@Biotechnology] market capitalization is $25.84M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRVS’s FA Score shows that 0 FA rating(s) are green whileHIND’s FA Score has 1 green FA rating(s).

  • CRVS’s FA Score: 0 green, 5 red.
  • HIND’s FA Score: 1 green, 4 red.
According to our system of comparison, CRVS is a better buy in the long-term than HIND.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRVS’s TA Score shows that 4 TA indicator(s) are bullish while HIND’s TA Score has 3 bullish TA indicator(s).

  • CRVS’s TA Score: 4 bullish, 4 bearish.
  • HIND’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, CRVS is a better buy in the short-term than HIND.

Price Growth

CRVS (@Biotechnology) experienced а +8.92% price change this week, while HIND (@Biotechnology) price change was -13.72% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.19%. For the same industry, the average monthly price growth was -5.74%, and the average quarterly price growth was +63.93%.

Reported Earning Dates

CRVS is expected to report earnings on Mar 05, 2026.

Industries' Descriptions

@Biotechnology (-2.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRVS($665M) has a higher market cap than HIND($25.8M). CRVS YTD gains are higher at: 66.542 vs. HIND (2.915).
CRVSHINDCRVS / HIND
Capitalization665M25.8M2,578%
EBITDA-35.45MN/A-
Gain YTD66.5422.9152,283%
P/E RatioN/AN/A-
Revenue0N/A-
Total Cash74.4MN/A-
Total Debt1.08MN/A-
FUNDAMENTALS RATINGS
CRVS vs HIND: Fundamental Ratings
CRVS
HIND
OUTLOOK RATING
1..100
2285
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
26
Undervalued
PROFIT vs RISK RATING
1..100
58100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
3682
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
8523

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HIND's Valuation (26) in the null industry is somewhat better than the same rating for CRVS (69) in the Pharmaceuticals Major industry. This means that HIND’s stock grew somewhat faster than CRVS’s over the last 12 months.

CRVS's Profit vs Risk Rating (58) in the Pharmaceuticals Major industry is somewhat better than the same rating for HIND (100) in the null industry. This means that CRVS’s stock grew somewhat faster than HIND’s over the last 12 months.

CRVS's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as HIND (100) in the null industry. This means that CRVS’s stock grew similarly to HIND’s over the last 12 months.

CRVS's Price Growth Rating (36) in the Pharmaceuticals Major industry is somewhat better than the same rating for HIND (82) in the null industry. This means that CRVS’s stock grew somewhat faster than HIND’s over the last 12 months.

CRVS's P/E Growth Rating (98) in the Pharmaceuticals Major industry is in the same range as HIND (100) in the null industry. This means that CRVS’s stock grew similarly to HIND’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRVSHIND
RSI
ODDS (%)
Bearish Trend 2 days ago
70%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
86%
Declines
ODDS (%)
Bearish Trend 15 days ago
90%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
87%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CRVS
Daily Signal:
Gain/Loss:
HIND
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MRGKX60.000.21
+0.35%
MFS Core Equity R6
NSGCX20.49N/A
N/A
Columbia Cornerstone Equity C
TVLRX12.52N/A
N/A
Touchstone Value R6
SBIYX13.04N/A
N/A
ClearBridge International Value I
BNIVX12.04N/A
N/A
Barrow Hanley International Value I

CRVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRVS has been loosely correlated with SYRE. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if CRVS jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRVS
1D Price
Change %
CRVS100%
-1.98%
SYRE - CRVS
44%
Loosely correlated
+0.83%
IPSC - CRVS
43%
Loosely correlated
+4.82%
RZLT - CRVS
40%
Loosely correlated
N/A
UPB - CRVS
40%
Loosely correlated
-2.62%
RGNX - CRVS
37%
Loosely correlated
-2.84%
More

HIND and

Correlation & Price change

A.I.dvisor tells us that HIND and CRVS have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HIND and CRVS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HIND
1D Price
Change %
HIND100%
-7.65%
CRVS - HIND
30%
Poorly correlated
-1.98%
VTVT - HIND
28%
Poorly correlated
+8.24%
ACET - HIND
20%
Poorly correlated
-3.72%
RNTX - HIND
4%
Poorly correlated
+3.28%
YDES - HIND
3%
Poorly correlated
-5.42%
More